Marte Helene Bjørk (born 1980) PhD in neuroscience, specialty registrar and postdoctoral fellow. She contributed to the literature review, and to the drafting and revision of the manuscript.
The author has completed the ICMJE form and declares no conflicts of interest.
Ivar Otto Gjerde (born 1947) specialist in clinical neurophysiology and neurology. He had the idea for the article and contributed to the clinical diagnosis of the patient.
The author has completed the ICMJE form and declares no conflicts of interest.
Charalampos Tzoulis (born 1979) PhD and specialist in neurology, with a particular interest in neurogenetics and movement disorders. He is head of the research group ‘Translational Science in Neurodegeneration and Aging’. He contributed to the neurological evaluation of the patient and prepared the illustration.
The author has completed the ICMJE form and declares no conflicts of interest.
Rune J. Ulvik (born 1947) specialist in clinical chemistry, senior consultant and professor. He contributed to the haematological evaluation of the patient, drafting and revision of the manuscript, and to the literature review.
The author has completed the ICMJE form and declares no conflicts of interest.
Laurence Albert Bindoff (born 1951) specialist in neurology and professor. He had the idea for the article and contributed to the neurological evaluation of the patient and to the revision and final approval of the manuscript.
The author has completed the ICMJE form and declares no conflicts of interest.
Department of Neurology
Haukeland University Hospital
and
Department of Clinical Medicine
University of Bergen
()
1.
Ellervik C, Marott JL, Tybjærg-Hansen A et al. Total and cause-specific mortality by moderately and markedly increased ferritin concentrations: general population study and metaanalysis. Clin Chem 2014; 60: 1419 – 28. [PubMed] [CrossRef]
2.
Weiss G. Modification of iron regulation by the inflammatory response. Best Pract Res Clin Haematol 2005; 18: 183 – 201. [PubMed] [CrossRef]
3.
Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol 2011; 55: 453 – 8. [PubMed] [CrossRef]
4.
Bacon BR, Adams PC, Kowdley KV et al. Diagnosis and management of hemochromatosis: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 328 – 43. [PubMed] [CrossRef]
5.
Pietrangelo A. The ferroportin disease. Blood Cells Mol Dis 2004; 32: 131 – 8. [PubMed] [CrossRef]
6.
Schneider SA, Hardy J, Bhatia KP. Syndromes of neurodegeneration with brain iron accumulation (NBIA): an update on clinical presentations, histological and genetic underpinnings, and treatment considerations. Mov Disord 2012; 27: 42 – 53. [PubMed] [CrossRef]
7.
Hogarth P. Neurodegeneration with brain iron accumulation: diagnosis and management. J Mov Disord 2015; 8: 1 – 13. [PubMed] [CrossRef]
8.
Ala A, Walker AP, Ashkan K et al. Wilson’s disease. Lancet 2007; 369: 397 – 408. [PubMed] [CrossRef]
9.
Pan PL, Tang HH, Chen Q et al. Desferrioxamine treatment of aceruloplasminemia: Long-term follow-up. Mov Disord 2011; 26: 2142 – 4. [PubMed] [CrossRef]
10.
Finkenstedt A, Wolf E, Höfner E et al. Hepatic but not brain iron is rapidly chelated by deferasirox in aceruloplasminemia due to a novel gene mutation. J Hepatol 2010; 53: 1101 – 7. [PubMed] [CrossRef]
11.
Abbruzzese G, Cossu G, Balocco M et al. A pilot trial of deferiprone for neurodegeneration with brain iron accumulation. Haematologica 2011; 96: 1708 – 11. [PubMed] [CrossRef]
12.
Feder JN, Gnirke A, Thomas W et al. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996; 13: 399 – 408. [PubMed] [CrossRef]
13.
Camaschella C, Poggiali E. Rare types of genetic hemochromatosis. Acta Haematol 2009; 122: 140 – 5. [PubMed] [CrossRef]
14.
Yoshida K, Furihata K, Takeda S et al. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995; 9: 267 – 72. [PubMed] [CrossRef]
15.
McNeill A, Pandolfo M, Kuhn J et al. The neurological presentation of ceruloplasmin gene mutations. Eur Neurol 2008; 60: 200 – 5. [PubMed] [CrossRef]
16.
Kono S. Aceruloplasminemia. Curr Drug Targets 2012; 13: 1190 – 9. [PubMed] [CrossRef]
17.
Tai M, Matsuhashi N, Ichii O et al. Case of presymptomatic aceruloplasminemia treated with deferasirox. Hepatol Res 2014; 44: 1253 – 8. [PubMed] [CrossRef]
This article was published more than 12 months ago and we have therefore closed it for new comments.
Published: 25 August 2015
Tidsskr Nor Legeforen 25 August 2015
doi:
10.4045/tidsskr.14.1115
Received 11 September 2014, first revision submitted 4 February 2015, accepted 20 May 2015. Editor: Lise Mørkved Helsingen.
If you do not see the PDF file or want to save the file, you can right-click on the PDF icon. Select «Save target / file as ...» and then retrieve the PDF file in, for example, Acrobat Reader.